Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR‐2 inhibitors
- 1 October 2021
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 355 (1), e2100278
- https://doi.org/10.1002/ardp.202100278
Abstract
Twenty new N-substituted-4-phenylphthalazin-1-amine derivatives were designed, synthesized, and evaluated for their anticancer activities against HepG2, HCT-116, and MCF-7 cells as VEGFR-2 inhibitors. HCT-116 was the most sensitive cell line to the influence of the new derivatives. In particular, compound 7f was found to be the most potent derivative among all the tested compounds against the three cancer cell lines, with 50% inhibition concentration, IC50 = 3.97, 4.83, and 4.58 µM, respectively, which is more potent than both sorafenib (IC50 = 9.18, 5.47, and 7.26 µM, respectively) and doxorubicin (IC50 = 7.94, 8.07, and 6.75 µM, respectively). Fifteen of the synthesized derivatives were selected to evaluate their inhibitory activities against VEGFR-2. Compound 7f was found to be the most potent derivative that inhibited VEGFR-2 at an IC50 value of 0.08 µM, which is more potent than sorafenib (IC50 = 0.10 µM). Compound 8c inhibited VEGFR-2 at an IC50 value of 0.10 µM, which is equipotent to sorafenib. Moreover, compound 7a showed very good activity with IC50 values of 0.11 µM, which is nearly equipotent to sorafenib. In addition, compounds 7d, 7c, and 7g possessed very good VEGFR-2-inhibitory activity, with IC50 values of 0.14, 0.17, and 0.23 µM, respectively.Keywords
This publication has 58 references indexed in Scilit:
- Synthesis and Evaluation of Some New (1,2,4) Triazolo(4,3‐a)Quinoxalin‐4(5H)‐one Derivatives as AMPA Receptor AntagonistsJournal of Heterocyclic Chemistry, 2013
- An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand BindingMolecular Cancer Therapeutics, 2011
- Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase InhibitorJournal of Medicinal Chemistry, 2010
- Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2Bioorganic & Medicinal Chemistry, 2009
- An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer CellsMolecular Cancer Research, 2008
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinaseBioorganic & Medicinal Chemistry Letters, 2005
- VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structuresExpert Opinion on Therapeutic Patents, 2005
- New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven AngiogenesisJournal of Medicinal Chemistry, 2000